A phase 2 study of eribulin in combination with pertuzumab and trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancer
Phase 2
- Conditions
- Advanced or recurrent HER2-positive breast cancer
- Registration Number
- JPRN-UMIN000014107
- Lead Sponsor
- SONG (South Osaka Network Group for Breast Cancer)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 43
Inclusion Criteria
Not provided
Exclusion Criteria
1. History of drug allergies with eribulin or pertuzumab or trastuzumab 2. Pregnant females or females of child-bearing potential2 3. Serious cardiac disorder 4. Not suitable for participation with any other reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method